NanoSIRNA

NanoSIRNA

NanosiRNA® COVID-19: specific antiviral treatment Medesis Pharma has a microemulsion technology that enables it to deliver these non-modified native siRNAs directly into the cytoplasm of all the organism’s cells via the HDL lipoprotein receptors, crossing the...
NanoManganese

NanoManganese

Medesis Pharma is developing a radioprotection drug to treat people irradiated following a civil or military nuclear accident (NP02 – NanoManganese®). Preclinical trials have been carried out with the French Armed Forces Biomedical Research Institute (IRBA)....
Medesis Pharma & Transgene prolongent leur accord de recherche collaborative

Transgene

TRANSGENE (Euronext Paris: TNG), a biotechnology company designing and developing virus-based immunotherapies against cancers and infectious diseases, has signed a collaborative research agreement with Medesis Pharma with exclusive license options to co-develop an...
Viral diseases

Viral diseases

Medesis Pharma is developing a radioprotection drug to treat people irradiated following a civil or military nuclear accident (NP02 – NanoManganese®). Preclinical trials have been carried out with the French Armed Forces Biomedical Research Institute (IRBA). (Study...